However, AFP has shown limited sensitivity in the clinical detection of early-stage liver cancer, and its levels can also be elevated in conditions such as chronic hepatitis and cirrhosis, which has led to some debate regarding its effectiveness in clinical settings [[31], [32], [33]]. This evidence concerns the gene AFP and chronic hepatitis.